Week in Review: WuXi Sells Stake in CMO Subsidiary; Lists on China OTC Exchange

WuXi PharmaTech sold a 5.55% stake in its chemical CMO operation, SynTheAll Pharma, for $28 million and listed the shares on China's OTC exchange; Sihuan Pharma partnered with CRO Covance Labs, which will help Sihuan coordinate global filings of its novel drugs; Merck Animal Health and China Animal Husbandry Industry signed an MOU to develop vaccines in China; Helsinn of Switzerland out-licensed China rights for an appetite-enhancing drug to the UK's Mundipharma; Solasia Pharma, a Japanese in-licensing company, acquired China-Japan rights to a novel treatment for oral mucositis from Camurus of Sweden; Luye Pharma completed three China Phase I trials of a novel anti-depressant; Hutchison MediPharma of Shanghai reported that fruquintinib met its primary endpoint in China patients with colorectal cancer; Berry Genomics of Beijing received CFDA premarket clearance on its non-invasive prenatal test for birth defects; and Pfizer closed down all of its China vaccine operations after its only approved vaccine in China, Prevenar, did not obtain China license renewal. More details.... Stock Symbols: (NYSE: WX) (HK: 0460) (NYSE: MRK) (SHA: 600195) (HK: 2186) (NYSE: PFE) Share this with colleagues: // //